{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001434868","name":"Esperion Therapeutics, Inc.","summary":"Esperion Therapeutics is a commercial-stage biopharmaceutical company focused on cardiovascular disease. It develops and commercializes oral, once-daily, non-statin medicines NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) to reduce LDL-C and cardiovascular risk in adults unable or unwilling to take statins. Products are approved by the FDA, European Commission, and Swissmedic, with international partnerships covering Japan, Canada, Israel, and Australia.","people":[],"products":[{"name":"NEXLETOL (bempedoic acid)","type":"service","description":"Oral, once-daily, first-in-class ACLY inhibitor approved by FDA to reduce LDL-C and cardiovascular risk in adults with or at high risk for CVD."},{"name":"NEXLIZET (bempedoic acid and ezetimibe)","type":"service","description":"Oral, once-daily combination tablet approved by FDA to reduce LDL-C and cardiovascular risk through complementary cholesterol synthesis and absorption inhibition."},{"name":"NILEMDO (bempedoic acid)","type":"service","description":"EC-approved ACLY inhibitor for adults with primary hypercholesterolemia or mixed dyslipidemia, with expanded cardiovascular risk reduction indication approved May 2024."},{"name":"NUSTENDI (bempedoic acid and ezetimibe)","type":"service","description":"EC-approved combination tablet for adults with primary hypercholesterolemia or mixed dyslipidemia, with expanded cardiovascular risk reduction indication approved May 2024."}],"partnerships":[{"partner_name":"Otsuka Pharmaceutical Co., Ltd.","partnership_type":"licensing","description":"Japanese collaborator who received approval from Japan's Ministry of Health to market NEXLETOL for hypercholesterolemia, with NHI pricing in Q4 2025.","start_date":null}],"affiliations":[],"origin":{"leaf":"1612200657b8a1350923ed16bb0d8a3f6986076d9d0f9b2c41a45907af3ca239","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"8beeaa8380f4f54644096232beb49ffd573f3f5489a631eb7d0d5a0fd2eea256","parent":"eac8d15389bc37a377941fa60c30abdda538c6f0f840ee69106f32eb00c5d5e0","source":"0001628280-26-016522","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":500,"hourly_limit":500,"remaining":0,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}